Centiva Capital
GILD icon

Centiva Capital’s Gilead Sciences GILD Stock Holding History

Centiva Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,700
Closed -$2.57M – 1941
2024
Q3 		$2.57M Buy
30,700
+15,000
+96% +$1.14M 0.05% 344
2024
Q2 		$1.08M Buy
15,700
+10,000
+175% +$667K 0.02% 734
2024
Q1 		$418K Sell
5,700
-4,300
-43% -$331K 0.01% 1080
2023
Q4 		$810K Sell
10,000
-22,100
-69% -$1.72M 0.02% 712
2023
Q3 		$2.41M Buy
32,100
+22,100
+221% +$1.7M 0.05% 335
2023
Q2 		$771K Sell
10,000
-10,000
-50% -$798K 0.02% 660
2023
Q1 		$1.66M Hold
20,000
– – 0.04% 460
2022
Q4 		$1.72M Sell
20,000
-30,000
-60% -$2.38M 0.05% 402
2022
Q3 		$3.08M Sell
50,000
-11,800
-19% -$744K 0.06% 246
2022
Q2 		$3.82M Sell
61,800
-55,100
-47% -$3.41M 0.09% 194
2022
Q1 		$6.95M Sell
116,900
-74,000
-39% -$4.73M 0.13% 105
2021
Q4 		$13.9M Buy
190,900
+190,230
+28,393% +$13.1M 0.29% 60
2021
Q3 		$47K Sell
670
-19,330
-97% -$1.36M ﹤0.01% 1132
2021
Q2 		$1.38M Buy
+20,000
New +$1.34M 0.03% 442
2021
Q1 		– Sell
-5,200
Closed -$302K – 1241
2020
Q4 		$302K Sell
5,200
-37,000
-88% -$2.23M 0.01% 650
2020
Q3 		$2.67M Buy
42,200
+9,500
+29% +$659K 0.18% 97
2020
Q2 		$2.52M Sell
32,700
-43,200
-57% -$3.31M 0.15% 85
2020
Q1 		$5.67M Buy
75,900
+7,700
+11% +$532K 0.25% 54
2019
Q4 		$4.43M Buy
68,200
+52,900
+346% +$3.44M 0.22% 96
2019
Q3 		$970K Buy
15,300
+14,700
+2,450% +$961K 0.06% 220
2019
Q2 		$41K Sell
600
-79,600
-99% -$5.24M ﹤0.01% 400
2019
Q1 		$5.21M Buy
80,200
+44,000
+122% +$2.92M 0.35% 44
2018
Q4 		$2.27M Buy
36,200
+2,300
+7% +$161K 0.18% 81
2018
Q3 		$2.62M Buy
33,900
+17,900
+112% +$1.35M 0.23% 68
2018
Q2 		$1.13M Sell
16,000
-1,000
-6% -$70.6K 0.24% 35
2018
Q1 		$1.28M Hold
17,000
– – 0.31% 22
2017
Q4 		$1.22M Buy
+17,000
New +$1.29M 0.1% 9

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Centiva Capital's GILD Position: Q2 2026 in Review

Centiva Capital increased its Gilead Sciences (GILD) stake by 79% in Q2 2026, buying an estimated $171K and bringing the position to 2,953 shares worth $373K. The position accounts for ﹤0.01% of the portfolio, ranked #1060.

Centiva Capital first reported a position in GILD in Q1 2018 and has held it in 27 quarters since. The position peaked at $6.01M in Q1 2023. 2,293 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Centiva Capital held 2,953 shares of Gilead Sciences worth $373K as of Q2 2026.
  • Centiva Capital bought 1,301 Gilead Sciences shares in Q2 2026, an estimated $171K.
  • Gilead Sciences made up ﹤0.01% of Centiva Capital's portfolio in Q2 2026, its #1060 holding.
  • Centiva Capital first reported a position in Gilead Sciences in Q1 2018 and has held it in 27 quarters since.
  • Centiva Capital's Gilead Sciences position peaked at $6.01M in Q1 2023.
  • 2,293 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.